Psychopharmacotherapy of Premenstrual Dysphoric Disorder-.

Psychopharmacol Bull

Naguy, MBBch, MSc, Alamiri, MD, ABPN, ScD, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Prof. El-Sheshai, MD, PhD, Senior Professor of Psychiatry, and Consultant Psychiatrist, Alexandria Faculty of Medicine, Egypt. Thiguti, MD, MRCPsych, Consultant General Adult Psychiatrist, UK.

Published: June 2022

Nearly forty percent of women with PMDD remain impaired and resistant to first-line agents. This reflects complexity and heterogeneity of etiopathogenesis at the core of PMDD. Some agents, in the pipeline, sound promising that might usher in a new sparkle in the psychopharmacology of PMDD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235312PMC

Publication Analysis

Top Keywords

psychopharmacotherapy premenstrual
4
premenstrual dysphoric
4
dysphoric disorder-
4
disorder- forty
4
forty percent
4
percent women
4
women pmdd
4
pmdd remain
4
remain impaired
4
impaired resistant
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!